Skip to main content
. 2019 Apr;10(2):300–306. doi: 10.21037/jgo.2018.11.08

Table 3. Overall survival for stage IV disease of all histologic subtypes.

Overall survival TC GCC NEC MANEC Adenocarcinoma
1-year OS 86.7% 85.7% 54.8% 75.0% 79.0%
2-year OS 86.7% 45.0% 54.8% 41.3% 60.9%
3-year OS 86.7% 32.9% 27.4% 26.3% 51.6%
4-year OS 86.7% 32.9% 27.4% 26.3% 40.8%

TC, typical carcinoids; GCC, goblet cell carcinoids; NEC, neuroendocrine carcinomas; MANEC, mixed adenoneuroendocrine carcinomas.